


DBCO-(PEG2-VC-PAB-MMAE)₂

Cat. No.:	HY-126690
CAS No.:	2259318-55-1
Molecular Formula:	C ₁₄₉ H ₂₂₄ N ₂₂ O ₃₂
Molecular Weight:	2835.5
Target:	Drug-Linker Conjugates for ADC
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	Powder -20°C 3 years

* The compound is unstable in solutions, freshly prepared is recommended.



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (17.63 mM; ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	0.3527 mL	1.7634 mL	3.5267 mL
	5 mM	0.0705 mL	0.3527 mL	0.7053 mL
	10 mM	0.0353 mL	0.1763 mL	0.3527 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

DBCO-(PEG2-VC-PAB-MMAE)₂ is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)₂ linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate^[1]. DBCO-(PEG2-VC-PAB-MMAE)₂ is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

IC₅₀ & Target

Auristatin

REFERENCES

[1]. Brian Lannutti, et al. Ror1 antibody immunoconjugates. WO2018237335A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA